Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.73 |
| ▸ | MMP7 | P09237 | 2/20 | 0.73 |
| ▸ | MMP14 | P50281 | 2/20 | 0.73 |
| ▸ | MMP1 | P03956 | 1/20 | 0.65 |
| ▸ | MMP3 | P08254 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | MMP13 | P45452 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651298 | 0.88 | HSD11B1 (0.66) | MMP2MMP7MMP14POLBALDH1A1 | |
| SCHEMBL6808132 | 0.87 | MMP2 (0.56) | MMP2MMP7MMP14MMP1MMP3 | |
| SCHEMBL29091331 | 0.85 | MMP2 (1.00) | MMP2MMP7MMP14MMP1MMP3 | |
| SCHEMBL13874609 | 0.81 | MMP2 (0.67) | MMP2MMP7MMP14MMP1MMP3 | |
| SCHEMBL28392708 | 0.80 | RECQL (0.73) | MMP2MMP7MMP14MMP1MMP3 | |
| SCHEMBL941038 | 0.80 | ALDH1A1 (0.54) | MMP2MMP7MMP14MMP1MMP3 | |
| SCHEMBL7385583 | 0.79 | ALDH1A1 (0.67) | MMP2MMP7MMP14POLBALDH1A1 | |
| SCHEMBL455924 | 0.79 | ALDH1A1 (0.69) | POLBALDH1A1SMN1; SMN2HSD11B1RECQL | |
| SCHEMBL11225865 | 0.78 | KMT2A (0.69) | MMP2MMP7MMP14MMP1MMP3 | |
| SCHEMBL293991 | 0.78 | PSIP1 (0.74) | MMP2MMP7MMP14MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20090099249-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP2 15/4885MMP7 17/4885MMP14 3/4885 |
| US-20090099249-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | MMP2 539/4885MMP7 958/4885MMP14 1887/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP2 15/4885MMP7 17/4885MMP14 3/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP2 15/4885MMP7 17/4885MMP14 3/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | MMP2 11/4885MMP7 15/4885MMP14 6/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | MMP2 11/4885MMP7 2/4885MMP14 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.